A methodology is formulated to analyze tumor recurrence data when its incidence rate is restricted due to medication. Analytic results are derived to make a probabilistic early warning of tumor recurrence free period of length τ; that is, the chance for a safe period of lengthτ is estimated. The captured data are length biased. Expressions are developed to extract and relate to counterparts of the non-length biased data. Three data sets are considered as illustrations: (1) patients who are given a placebo, (2) patients who are given the medicine pyridoxine and (3) patients who are given the medicine thiotepa.
Introduction
Cancer is the second major cause of death after cardiovascular deaths in USA. Tumor, an abnormal growing of cells in the brain, is an important category in the cancer group and remains mysterious to medical researchers. Whether a tumor is a benign or malignant type, its recurrence time must be speculated for an efficient treatment and an early warning of its recurrence time is crucial. The early warning provides a basis for the decision of whether to continue the same medicine or change to another medicine. The medical community relies heavily on an answer to the question: what do the data suggest? The statistical community is obligated to devise an appropriate statistical methodology to analyze a patient's data to make a probabilistic early warning regarding whether a time period of length τ will be tumor recurrence free.
Ramalingam Shanmugam is a Professor in the School of Health Administration. His research interests include multivariate data modeling, informatics, optimal decision support systems, and health/medical application of statistics. Email him at: rs25@txstate.edu.
The current literature does not contain information to answer these questions. To compensate for the gaps in this area, this study was undertaken to introduce a new statistical methodology to fulfill the need for making an early probabilistic warning of tumor recurrence during a tumor free period of length τ.
Let T > 0 represent a random time in which a tumor (malignant or benign) reoccurs in a patient. Given the collected data on his/her recurrence times, could a future period of length τ be tumor recurrence free? Suppose that the uncertainty in T is governed by non-observable incidence parameters θ < β, where θ and β portray the tumor recurrence rate and its restriction level respectively. A restriction on the incidence rate exists due to the effect of the given medication. Let ν > 0 be the threshold time parameter connecting T, θ and β. To capture their intricacies, consider the probability density function:
;0
for T > ν > 0 in terms of θ and β. The expected and variance time of the probability pattern in (1) are, respectively, 
A recurrence is missed if the observation period is too short; a longer observation period increases the chance of recording another tumor recurrence. This concept is length biased sampling (see Zelen & Feinlieb, 1969 for details on length bias phenomenon). The length bias alters the statistical assessment of the recurrence trend. A caution is necessary regarding how the lengthbiased data are analyzed and interpreted. When the equal random sampling is replaced by proportional length biased sampling, the lengthbiased version of the model in (1) is appropriate for the recurrent tumor times as follows:
;0 
where arg t eted tumor μ denotes the actual average tumor recurrence time. The probability density functions in (1) and (4) are interrelated and their relations are used to forecast tumor recurrence in this study by employing a methodology to analyze tumor recurrence data when its rate is restricted due to medication. Using the analytic results, an early warning of the next tumor recurrence free period of length τ is made. Various pertinent information in the lengthbiased data are extracted and compared to their counterparts under non-biased data.
Results
To identify whether a tumor recurrence free period of length τ exists at the earliest time possible, understanding its patterns is prerequisite. Since the last major tumor recurrence, the probability that a next recurrence will happen within a selected time τ > 0 is 
Expression (7) suggests a relation between the actual average tumor recurrence time Based on this, the incidence parameters of the tumor recurrence probability pattern in (4) are estimable with 
Thus, with estimates for (9), (10) and (11), the survival probability in (6) 
The factor
β in (13) with a single incidence (that is, n = 1), signifies the over-estimated proportion of the chance of having a minimal safe period τ . This proportion of over-estimate diminishes as the patient experiences more recurrences (that is, as n increases).
Examples
To illustrate results, tumor data from Andrews and Herzberg (1990) were selected, these data show placebo, pyridoxine drug and thiotepa drug groups. The mean and variance of tumor recurrence times are calculated for each patient along with the captured survivability for each patient using (5) and the cofactor using (6). (See Tables 1A, 2A and 3A. ) For example, the patient with ID# 13 in the placebo group has 0.71 captured chance of survivability without tumor recurrence in 12 months and the actual survivability chance is 0.03 times the captured chance of surviving without tumor recurrence.
Using expressions (9) through (11), the incidence parameters are estimated and are displayed in Tables 1B, 2B and 3B. For example, the parameter estimates φ , ν and the restriction gap (.) in (.) θ β < on the incidence rate for patient #13 in the placebo group are 0.53, 2.14 and 3 respectively; patient #15 is an anomaly. Results presented in in Tables 1B, 2B and 3B also show the chance of a patient having a safe period without any tumor recurrence for the next twelve months is calculated using (13), and estimates for how much the over-estimation might have been in the length biased data are calculated using (14).
The restriction level in (12) Figures 1, 2 and 3 illustrate the pattern of actual survival chance in terms of the data captured for placebo, pyridoxine drug and thiotepa drug groups. Note that one outlier case (patient #15) is present in the placebo group. In addition, it is notable that the trend for the pyridoxine group is a reversed direction compared to the other two groups; patients in the pyridoxine drug group display an upward curve while the placebo group and the thiotepa drug group have downward curves.
Conclusion
If other predictor variables are available, a logistic regression can be built for patients. In addition, the more and less important predictors can be identified based on the estimate of survivability without a tumor recurrence in the next 12 months. 
